Evidence map›Paper›PMID 40011312›Full record

ArticleAAPS PharmSciTech2025

Cellular Uptake and Trafficking of Lipid Nanocarriers Using High-Resolution Electron Microscopy.

Thilo Faber, Alf Lamprecht

Abstract read
PubMed Publisher
In one paragraph

Article in AAPS PharmSciTech, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Thilo FaberDepartment of Pharmaceutics, Institute of Pharmacy, University of Bonn, Gerhard-Domagk-Str 3, 53121, Bonn, Germany.
Alf LamprechtDepartment of Pharmaceutics, Institute of Pharmacy, University of Bonn, Gerhard-Domagk-Str 3, 53121, Bonn, Germany. alf.lamprecht@uni-bonn.de.ORCID http://orcid.org/0000-0002-4492-1579

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lipid based nanocarriers are a commonly used drug delivery system with cargos ranging from small molecules to complex RNA-based therapies. There are several hypotheses how such carriers can enter the cell, in which organelles they reside, and how they cross or escape the endo-lysosomal system. To provide additional insights, the cell-nanocarrier interplay was visualized exemplarily with lipid-based nanocarriers and macrophage-like cultured cells (J774A.1 cells) using high resolution electron microscopy. Nanocarrier uptake into J774A.1 cells was detectable after the first 15 min by intracellular accumulation of electron-dense material. These accumulations were identified as lysosomes and lipid droplets, indicating complete degradation and a subsequent formation of storage organelles as early as 15 min. Inhibition of lysosomal acid lipase did not block lipid droplet formation, but rather resulted in accumulation of lipid droplets within lysosomes. This suggests that other cellular lipases already degrade acylglycerols before they reach lysosomes. Chloroquine co-treatment allowed visualization of nanocarriers inside endosomal vesicles, multivesicular bodies, and lysosomes.

Indexed as

Drug CarriersLipidsNanoparticlesAnimalsBiological TransportCell LineChloroquineDrug Delivery SystemsEndosomesLysosomesMacrophagesMiceMicroscopy, ElectronSterol EsteraseChloroquineDrug CarriersLipidsSterol EsteraseIntracellular traffickingLipid nanocarriersScanning transmission electron microscopy (STEM)

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.